Ralinepag vs Treprostinil (L606)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Pulmonary Arterial Hypertension
Shared mechanism: IP receptor (prostacyclin pathway) · full Pulmonary Arterial Hypertension pipeline
Ralinepag
Developed by United Therapeutics under a licence from Arena Pharmaceuticals, Inc.
NCT03626688 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo-controlled, event-driven Phase 3 trial with 687 patients in the full analysis set (728 randomized; 41 patients from sites in China excluded), measuring time to first clinical worsening event as the primary endpoint. The peer-reviewed report in The Lancet gives a hazard ratio of 0.45 (95% CI 0.33-0.62; p<0.0001) for ralinepag versus placebo, with more discontinuations for adverse events on ralinepag (19% vs 3%).
Next expected readout: December 2026 · NCT03683186 (registry estimate)
Reported efficacy
Time from randomization to the first adjudicated protocol-defined clinical worsening event (The study duration was event-based. This parameter was assessed from randomization until the conclusion of the study, up to 3 years): Time to first adjudicated clinical worsening event (ADVANCE OUTCOMES): HR 0.45 (95% CI 0.33-0.62) vs placebo, a 55% risk reduction, p<0.0001. (met)
Result source: NCT03626688
Treprostinil (L606)
Developed by Liquidia Corporation under a licence from Pharmosa Biopharm Inc.
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for Pulmonary Arterial Hypertension
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Treprostinil (L606): no structured comparison results are available for Pulmonary Arterial Hypertension.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Ralinepag
show 16 more results
Available safety results
Ralinepag
| Dropout rate | 44.4% NCT02279745 · Phase 2 · registry result, not featured evidence show 1 more result15% NCT02279160 · Phase 2 · registry result, not featured evidence |
|---|---|
| Discontinued due to AEs | 15.6% NCT02279745 · Phase 2 · registry result, not featured evidence show 1 more result— NCT02279160 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 46.7% NCT02279745 · Phase 2 · registry result, not featured evidence show 1 more result10% NCT02279160 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | headache 64.4% diarrhoea 37.8% pain in jaw 33.3% NCT02279745 · Phase 2 · registry result, not featured evidence show 1 more resultheadache 77.5% (placebo 28.6%) nausea 50% (placebo 23.8%) diarrhoea 47.5% (placebo 14.3%) NCT02279160 · Phase 2 · registry result, not featured evidence |
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ralinepag's landscape · Treprostinil (L606)'s landscape